FDAsafety guidance72% confidence
Drug Trials Snapshots: PALSONIFY
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (immunology) as Boehringer Ingelheim.
Regulatory Analysis
PALSONIFY is a somatostatin receptor analog for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
Supporting Context
- Therapeutic area
- Pulmonology · Lung Fibrosis
- Sub-indication
- Immunology
Related signal: Boehringer Ingelheim's Nerandomilast Trial for Lung Fibrosis in Autoimmune Diseases